Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vectura Group has entered into an agreement with a US division of an undisclosed pharma firm for VR315, a combined therapy for asthma/COPD.
Subscribe to our email newsletter
The tie up allows the US based company to carry forward the clinical development, manufacturing and commercialization of VR315 product.
Vectura will provide support for the US development of VR315, for which it will receive an initial payment of $10m and up to $35m upon achievement of pre-determined development milestones.
The undisclosed company is also responsible to pay a royalty from all VR315 US sales to Vectura.